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Utility and Yield of Genetic Testing Leading to a Definitive Neuromuscular
or Neuropathic Diagnosis at a Rural Outpatient Neurology Clinic Affiliated
with a University Health Center in West Virginia over 4 Years
Holly Farkosh, MS41, Dominika Lozowska, MD2

ABSTRACT
Background: Clinicians are increasingly relying on genetic testing to pinpoint definite
diagnoses. A more general diagnosis of neuropathy or neuromuscular disease like
myopathy can be narrowed down substantially using genetic testing. Because carrier
status is of utmost importance in reproductive matters, pathogenic results can
prognosticate the future course of the illness and help plan ahead for treatment and
social supports. Given the expense of genetic testing, it is important to assess the
cost-benefit ratio to determine whether it is worthwhile to collect genetic samples.
The purpose of the study was to determine the likelihood of obtaining a conclusive
confirmatory diagnosis through genetic testing (measured as the percent of positive
results obtained out of all the submitted samples).
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Methods: A single clinician’s record of genetic test outcomes was reviewed spanning
four years from July 2015 to June 2019 to identify those who had submitted genetic
samples to Invitae, a commercial lab in California that offers affordable genetic
testing. All patients were evaluated for complaints of neuromuscular and neuropathic
nature using the standard of care workup that included a physical exam, lab tests,
nerve conduction study (NCS), electromyography (EMG), and/or muscle biopsy
before sending out for genetic testing. The positive, negative, and indeterminate
genetic diagnoses were tabulated, and the individual disease entities’ prevalence was
determined.
Results: Of the patients who participated in genetic testing, 96 were diagnosed with
neuropathic conditions and 59 with neuromuscular conditions. The patients’ health
records did not have to be mined for results because the clinician’s Invitae account
contained de-identified requisition numbers linked to their results. The patients in the
neuromuscular group had twice as many positive results as those in the neuropathic
group. There were about three times as many normal results in the neuropathic
group compared to the neuromuscular group. Around half of all test samples showed
indeterminate results containing variants of unknown significance (VOUS), which were
not indicative of any pathology and were considered inconclusive.
Conclusion: Based on the study findings, there were 17.7% and 35.6% positive (meaning
pathogenic) results, respectively, among neuropathic and neuromuscular cases sent
off for genetic analysis. While 38 out of 155 total cases makes up a small, 24.5% yield
of abnormal results, genetic studies are still a worthwhile addition to investigating
neuropathic and neuromuscular cases.
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INTRODUCTION
Genetic testing has come to the forefront as one
of the tools a neurologist uses more frequently
than ever as the next step for patient care after
a detailed history, careful exam, and appropriate
workup, including labs and EMG/NCS studies. It
may even eliminate the need for a muscle, skin,
or nerve biopsy, depending on the particular
situation and the clinician’s judgment. This article is
a retrospective review of all genetic results for nextgeneration, sequencing-based gene panel testing
of patient samples obtained at a neurology clinic

by one provider to determine the percentage of
success in reaching a definitive diagnosis (i.e., a
particular type of neuropathy or myopathy) and
thus prognosticating future disease course and
implications for relatives if any.
METHODS
This study was approved by the Marshall University
Institutional Review Board (IRB), protocol number
1427509. The research design consisted of a
retrospective record review of de-identified genetic

FIGURE 1. The 102 genes tested for in the Invitae comprehensive neuropathy disorders panel.

FIGURE 2. The 103 genes tested for in the Invitae comprehensive neuromuscular disorders panel.
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results for neurology patients who presented
to a single practitioner’s outpatient clinic with
complaints suggestive of a neuromuscular
problem such as weakness, atrophy, or myalgias,
versus a neuropathic problem such as numbness,
paresthesias, or falls. Patients already had a suitable
workup and gave their consent to submit a genetic

sample to gather more definitive information
about their condition and its inheritance pattern
or to confirm the clinical diagnosis. The Invitae
neuropathy panel contained 102 genes (figure 1),
and the neuromuscular panel contained 131 genes
(figure 2). Inclusion criteria were to include those
who presented with neuropathic and neuromuscular

FIGURE 3. Pie chart of Invitae neuropathy panel results.

FIGURE 4. Pie chart of Invitae neuromuscular panel results.
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complaints and who were studied with Invitae’s
neuropathic or neuromuscular comprehensive gene
panel. Exclusion criteria were to exclude patients
who were genetically tested for other conditions due
to symptoms concerning Parkinson’s, Alzheimer’s,
and neurofibromatosis. Referrals came from tertiary
or private offices in the local tri-state area (West
Virginia, Kentucky, and Ohio), the VA hospital, and

colleagues in practice. Neurophysiology using
NCS/EMG studies was employed in the majority of
cases to distinguish myopathic from neuropathic
conditions and to grade the severity. Data entry
consisted of arranging anonymous findings
consisting of 6 digit requisition numbers in an excel
spreadsheet and then tabulating the mutation(s)
involved, carrier status, pathogenicity, or lack thereof,

FIGURE 5. Comparison of abnormal genetic results.

FIGURE 6. Listing of the number of the particular gene mutations found via the
Invitae neuropathic panel and the associated disease conditions caused by them.
AD (autosomal dominant), AR (autosomal recessive).
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FIGURE 7. Listing of the number of the particular gene mutations found via the Invitae
neuromuscular panel and the associated disease conditions caused by them. AD (autosomal dominant), AR (autosomal recessive).

along with the presence of inconclusive variants of
unknown significance (VOUS).
RESULTS
One hundred and fifty-five cases were identified as
eligible for inclusion in the study. Of these, 96 had
been diagnosed with neuropathy and underwent
genetic testing with the Invitae comprehensive
neuropathy disorders panel, and 59 had been
diagnosed with a neuromuscular condition, such as a
probable myopathy, and underwent genetic testing
with the Invitae comprehensive neuromuscular
disorders panel. Out of 96 neuropathic cases, 17 had
abnormal, 36 had normal, and 43 had indeterminate
results. Of the 17 abnormal neuropathic cases, 15
had an autosomal dominant or X-linked pathogenic
mutation pattern, and two were carriers of an
autosomal recessive (AR) pathogenic mutation. Out
of 59 neuromuscular cases, 21 had abnormal, 8 had
normal, and 30 had indeterminate results. Of the 21
abnormal neuromuscular cases, 12 had an autosomal
dominant pathogenic mutation pattern, and 9 were
carriers of an autosomal recessive (AR) pathogenic
mutation. The major disease categories identified are
described in figure 6 and figure 7. There were twice
as many positive results in the neuromuscular group
(35.6%) as in the neuropathic group (17.7%). There
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were about three times as many normal results in the
neuropathic group (37.5%) as in the neuromuscular
group (13.6%). The yield of variants of unknown
significance (VOUS) was roughly half of all the tests
sent: 44.8% in the neuropathic group and 50.8% in
the neuromuscular group.
DISCUSSION
The literature does not contain a lot of specific
data about the prevalence of neuropathic and
neuromuscular disease in West Virginia. In 1987,
Benson et al. mentioned an Appalachian region
kindred with familial amyloid polyneuropathy.1 West
Virginians may be somewhat under-represented
in the field of genetic research for various reasons
such as poverty level, lack of access to higher
education centers and resources due to financial and
transportation difficulties, etc., but when looking at
cancer as a leading cause of death in Appalachia,
Llanos et al. studied “predictors of willingness to
participate in biospecimen donation and biobanking
among Appalachian adults” and found that 97%
of those who agreed to be tested were willing to
have their samples sent for genetic studies.2 We
aimed to expand knowledge about which genetic
conditions might be uncovered at a single clinician’s
neurology practice in 4 years at a rural outpatient
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neurology clinic in WV. We had 155 patients who
expressed interest in genetic testing, excluding those
who agreed to be tested for symptoms other than
neuropathic or neuromuscular. One limitation of our
study is that the number of cases sent for genetic
testing is dependent on the clinical acumen of the
clinician and the workup leading up to the decision
to extend genetic testing to patients. While it was
not feasible to obtain second opinions on all 155
patient cases, if we did, it might have been useful
to only send those cases for genetic testing, where
the other clinician saw a need for it too. Another
limitation is the small sample size, which may not
be representative of other regions of WV. We could
have, perhaps, captured a larger number of cases if
we invited other neurology practices to participate
in our study, perhaps even the other universitybased practice in WV that also frequently performs
genetic testing. The study drew cases from only
one clinician’s practice, so the case numbers are low
due to the clinician seeing other general neurology
cases besides patients voicing neuropathic and
neuromuscular problems. In a more large-scale
population study in Northern England, where
prevalence was calculated per 100,000 inhabitants,
they were able to confirm the presence of a
condition by genetic testing in 75.7% of those whom
they studied.3
Usually, the diagnostic algorithm in a neurology
clinic involves asking about developmental history,
specifically, the presence of contractures at birth,
developmental milestones, ability to keep up
with peers in races, a pattern of wearing out shoe
soles, cramps, paresthesias, and any inheritance
pattern among relatives with similar symptoms.
The exam may reveal pes cavus, thin calves, sensory
loss, foot drop, proximal weakness, or scapular
winging. After sending a combination of labs that
may include but aren’t limited to A1c, CPK, B12,
and serum electrophoresis, an NCS/EMG study
becomes instrumental in pinpointing a need for
further testing. Genetic testing with next-generation
sequencing (NGS) may help uncover an explanation
for a multisystem disease process of neuropathic or
myopathic disease and help to pinpoint a specific
neuropathy subtype, of which there are many. While
whole-exome sequencing is being clinically used, it is
more costly, has a higher false-positive rate, a longer
turnaround time, and is more difficult to interpret
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compared to targeted NGS.4 Our study notably
confirmed that among the cases suspected of having
a neuropathic condition, as shown in figure 6, there
were 14 cases of different CMT subtypes, 2 carriers
of different CMT subtypes, and 1 of Hereditary
Sensory Autonomic Neuropathy type 1c. Among CMT
sufferers, the most common was a PMP22 mutation
(5 cases), then GJB1 mutation (4 cases), then MFN2
mutation (3 cases). There was 1 case each of MPZ,
SPTLC2, and LITAF mutation causing CMT. CMT
is quite prevalent in the general population (1 in
25,000), so that was not unexpected.5
In terms of neuromuscular disease, as shown in
figure 7, our study predominantly confirmed 3 cases
of paramyotonia congenita, 3 cases of Bethlem
myopathy, 2 cases of myotonia congenita, 2 cases
of Laing distal myopathy, 1 case of centronuclear
myopathy, and 1 case of spinal muscular atrophy.
There were three carriers of nemaline myopathy
and 6 carriers of other conditions (limb-girdle
muscular dystrophy 2H, congenital myasthenic
syndrome, SMA, myotonia congenita, and muscular
dystrophy-dystroglycanopathy C14). Curiously, 1
patient was a carrier of 2 disease conditions (SMA
and hereditary spastic paraparesis). This shows that
sometimes, sending a panel containing multiple
genes is convenient because it can identify several
mutations at once. However, casting a wide net for
testing (including genetic testing) is still considered
controversial, given that Greenberg et al stated
the viewpoint that “testing should be performed
as targeted studies, sometimes sequentially, but
not as wasteful panels of multiple genetic tests
performed simultaneously.”6 It appears that the
clinician in our study sent off more test kits for
neuropathy compared to the number of kits sent
for neuromuscular testing but received fewer
confirmations of genetically proven neuropathy,
which indicates a potential tendency to overtest patients with a neuropathy presentation.
This discrepancy could be due to the fact that
neuropathies have many other potential etiologies
besides being inherited, such as being caused by
vitamin deficiencies, systemic illness (diabetes
and hepatitis C), or by medications (colchicine,
amiodarone, or certain chemotherapeutics). The ease
of sending a genetic panel may lead to over-reliance
on it.
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Genetic testing is important because it can be
informative about comorbidities that otherwise
may not be immediately apparent. For example, the
phenotype of high arches and hammertoes may hint
at the presence of CMT. While a diagnosis may be
made clinically, certain CMT subtypes like CMT type 6
coincide with ocular conditions that may be missed,
were it not for genetic testing, and optic atrophy can
be discovered earlier and sufficiently monitored. In
the case of a patient who is misdiagnosed as CIDP
based only on soft symptoms and prior NCS studies
and is refractory to steroids or immunosuppressive
treatment, genetic testing could potentially help
reclassify him as CMT 1a. Sometimes, when looking
for another suspected mutation, a discovery is
made of a completely different sort, as in our study,
where one ALS patient was found to be a carrier
of AR spinal muscular atrophy. Another patient
was found to be a carrier of 2 AR mutations: spinal
muscular atrophy and hereditary spastic paraplegia
11. Normally, familial testing would be offered, but
the ALS patient was adopted, and the other patient’s
relative wasn’t interested in getting tested because
she was unaffected.
One drawback of large panel genetic testing is the
number of variants of unknown significance (VOUS)
reported. VOUS are somewhat difficult to explain to
the patient because they represent polymorphisms
of uncertain significance. Those with indeterminate
results may get reclassified in the future, as Invitae
scans Exome Aggregation Consortium (ExAC)
databases for other cases of VOUS reported. It is
easier nowadays than previously to send a genetic
test, especially on saliva, which can be collected
in the office. The genetic test allows for arrival
at a precise diagnosis which otherwise may not
be established with confidence. A condition like
muscular dystrophy or inherited neuropathy can be
narrowed down with genetic testing to a subtype or
even precisely characterized sooner than could be
done by clinical exam or biopsy alone. There is often
not enough time in the clinic to do a full pedigree
or to examine close relatives in the office. A phone
consultation via telemedicine with a geneticist
may prove helpful when the lack of a geneticist
on site prevents patients from attending genetic
consultations for post-diagnosis counseling or
arranging familial testing.
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In terms of clinical application of genetic testing,
let’s take the example of a hypothetical Duchenne
muscular dystrophy case. If the clinician has a high
degree of suspicion upon seeing a young male
patient with enlarged calves, who is walking on
tiptoes and has elevated creatinine phosphokinase
enzyme, a quick genetic test for large deletion/
duplication in the DMD gene or genetic sequencing
for smaller point mutations can be obtained to
arrive at the answer faster, rather than waiting to
do a rather invasive EMG test or a muscle biopsy to
check if dystrophin protein is absent in the patient’s
muscle fibers. The earlier the patient is diagnosed,
the earlier he will have access to supportive care,
orthotics, assistive devices, and treatments like
steroids that help preserve respiratory function
and delay ambulatory decline. His female relatives
can also be tested to see if they are symptomatic
carriers, which screens them for heart problems and
weakness they may develop and gives them access
to echocardiograms and specialist care, which they
might not otherwise get. The personal impact of
genetic testing on someone who, for example, has
early motor neuron disease but very few symptoms
and is still functioning may provide early genetic
confirmation of the condition before progressive
terminal illness ensues. This would allow some time
for the patient to visit distant relatives or undertake
travel before he becomes too ill to travel or would
allow time for him to move to a better-adapted
house that may be easier to access and navigate.
In a case of spinal muscular atrophy (SMA), prior
knowledge of having an inheritable mutation in
the family pedigree may facilitate discussion of
considerations for choosing alternative fertility
options such as surrogacy or adoption to avoid
passing on a condition that may have terminal or
severe consequences to the next generation. Overall,
genetic testing is highly conducive to streamlining
and facilitating targeted care and treatment for
patients.
CONCLUSION
The accumulated results showed the breadth of
neuromuscular and neuropathic genetic conditions
present in a typical patient population of a university
outpatient neurology clinic in rural West Virginia
(WV) over the course of 4 years during a single
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clinician’s usual neurology workup supplemented
by the extra step of genetic testing. Genetic testing
of this population led to the identification of various
heritable diseases such as CMT, paramyotonia
congenita, Bethlem myopathy, congenital myotonia,
and other rare conditions, the knowledge of which
benefited the patients and their families.
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